Brainomix will distribute Neuro.MS, Pixyl’s Software as a Service (SaaS) solution for diagnosis and treatment of patients with multiple sclerosis (MS), exclusively in the UK and Ireland, the Nordics and key markets across Eastern Europe
UK-based medical software developer Brainomix has partnered with French medical imaging company Pixyl, to expand its offering with multiple sclerosis treatment solution.
Under the collaboration, Brainomix will distribute Pixyl’s software-as-a-Service (SaaS) solution, intended for the diagnosis and treatment of patients with multiple sclerosis (MS).
The solution, dubbed Neuro.MS, leverages advanced deep-learning technology to provide clinicians with clinically relevant information for neurological disorders such as MS.
Brainomix will distribute Pixyl’s SaaS solution exclusively in the UK and Ireland, the Nordics, and important markets across Eastern Europe.
Brainomix co-founder and CEO Michalis Papadakis said: “We are excited to embark on this partnership with Pixyl – a company with whom we share a common vision focused on developing innovative, AI-powered solutions that can enhance diagnostic and treatment decisions.
“We recognized that there was an opportunity to form these types of third-party technology partnerships, as a way of offering our customers a broader set of AI-enabled solutions.
“We have achieved great success with our e-Stroke platform, and now look to apply that expertise to Pixyl’s Neuro.MS SaaS solution, helping to spur wider clinical adoption of this best-in-class technology.”
Neuro.MS, is a CE mark approved Class 2A product that automatically analyses brain MRI images to identify, quantify and track abnormalities within 5 minutes.
It provides access to quantified measures of lesion volume and brain atrophy, along with quantified and classified white matter hyperintensities.
The partnership allows Brainomix to offer Pixyl’s Neuro.MS solution to its existing customer base, alongside its comprehensive stroke imaging solution, dubbed e-Stroke platform.
Established in 2015, as a spin-out of the French labs Inria and Inserm, Pixyl has a team of more than 20 people, and is focused on the next-generation predictive imaging solutions.
Pixyl co-founder and CEO Senan Doyle said: “Leveraging Brainomix’s large installed base and dedicated sales force in some of Europe’s leading markets represents a strategic step in our vision to broaden the adoption of AI-powered, clinically relevant solutions to drive better patient outcomes in the neurology imaging space.”
Earlier this month, Brainomix has teamed up with Visionable, a provider of a real-time clinical collaboration platform, to enhance the delivery of care for stroke patients.